Removal of natural anti-αGal antibodies elicits protective immunity against Gram-negative bacterial infections

Front Immunol. 2023 Aug 18:14:1232924. doi: 10.3389/fimmu.2023.1232924. eCollection 2023.

Abstract

Antibody-dependent enhancement (ADE) of bacterial infections occurs when blocking or inhibitory antibodies facilitate the infectivity of pathogens. In humans, antibodies involved in ADE of bacterial infections may include those naturally produced against Galα1-3Galβ1-4GlcNAcβ (αGal). Here, we investigate whether eliminating circulating anti-αGal antibodies using a soluble αGal glycopolymer confers protection against Gram-negative bacterial infections. We demonstrated that the in vivo intra-corporeal removal of anti-αGal antibodies in α1,3-galactosyltransferase knockout (GalT-KO) mice was associated with protection against mortality from Gram-negative sepsis after cecal ligation and puncture (CLP). The improved survival of GalT-KO mice was associated with an increased killing capacity of serum against Escherichia coli isolated after CLP and reduced binding of IgG1 and IgG3 to the bacteria. Additionally, inhibition of anti-αGal antibodies from human serum in vitro increases the bactericidal killing of E. coli O86:B7 and multidrug-resistant Klebsiella pneumoniae and Pseudomonas aeruginosa. In the case of E. coli O86:B7, there was also an improvement in bacteria opsonophagocytosis by macrophages. Both lytic mechanisms were related to a decreased binding of IgG2 to the bacteria. Our results show that protective immunity against Gram-negative bacterial pathogens can be elicited, and infectious diseases caused by these bacteria can be prevented by removing natural anti-αGal antibodies.

Keywords: Gram-negative bacteria; anti-αGal antibodies; antibody-dependent-enhancement of infection; protective immunity; removal of antibodies.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Anti-Bacterial Agents
  • Escherichia coli*
  • Gram-Negative Bacterial Infections*
  • Humans
  • Immunoglobulin G
  • Mice
  • Punctures

Substances

  • Immunoglobulin G
  • Anti-Bacterial Agents

Grants and funding

This work was supported by the “Fondo de Investigaciones Sanitarias” (FIS) grant PI13/01098 from the Carlos III Health Institute, Spanish Ministry of Health. SO-A was the beneficiary of a pre-doctoral research position funded by Pla de Doctorats Industrials del Departament de Recerca i Universitats de la Generalitat de Catalunya (2018 DI 021). DB-G was the beneficiary of a post-doctoral research position funded by the European Union Seventh Framework Programme (FP7/2007-2013) under Grant Agreement 603049 (TRANSLINK). The work of NK, NS, and NB was supported by grant #14-14-00579 from the Russian Science Foundation.